Related Experiment Video
Updated: Jan 20, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
Takashi Kawahara1, Tappei Takeshima1, Yasuhide Miyoshi1
1Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Abstract:
COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwent right nephrectomy in 2015. In 2017, iliac bone metastasis was found and consequently lung metastasis was developed. Pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers during pazopanib treatment for more than two years and the size and number of lung metastases decreased. We herein report a case of successful control of metastatic renal cell carcinoma for more than two years using pazopanib treatment.
Insights
Sunitinib and pazopanib showed similar survival outcomes in metastatic renal cell carcinoma. Pazopanib demonstrated better quality of life and early tumor shrinkage, with a case study showing over two years of successful disease control.
Area of Science:
- Oncology
- Medical Treatments
Background:
- The COMPARZ study compared sunitinib and pazopanib for metastatic renal cell carcinoma (mRCC).
- Renal cell carcinoma is a significant cause of cancer-related mortality.
- Understanding comparative treatment efficacy and patient-reported outcomes is crucial for mRCC management.
Observation:
- A 70-year-old male with metastatic renal cell carcinoma (iliac bone and lung metastases) was treated with pazopanib.
- The patient received pazopanib 800 mg daily for over two years.
- No abnormal liver function markers were observed during treatment.
Findings:
- The COMPARZ study found no significant differences in progression-free survival or overall survival between sunitinib and pazopanib.
- Pazopanib demonstrated superior outcomes in early tumor shrinkage and quality of life compared to sunitinib.
- The case study illustrated successful, long-term (over two years) disease control in metastatic renal cell carcinoma with pazopanib, with notable reduction in lung metastasis size and number.
Implications:
- Pazopanib offers a favorable alternative to sunitinib for metastatic renal cell carcinoma, particularly regarding quality of life and early tumor response.
- Long-term pazopanib treatment can achieve durable disease control in select metastatic renal cell carcinoma patients.
- These findings support personalized treatment strategies in metastatic renal cell carcinoma, considering both survival and patient-centered outcomes.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Long-term Depression
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...